Get started
Author

Paolo Ambrosini

NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer
2024 · Federico Nichetti, Simone Rota, et al. · JAMA Network Open · 142
PDF
Human NK cells at early stages of differentiation produce CXCL8 and express CD161 molecule that functions as an activating receptor
2012 · Elisa Montaldo, Chiara Vitale, et al. · Blood · 73
PDF
IL‐1β inhibits ILC3 while favoring NK‐cell maturation of umbilical cord blood CD34 + precursors
2015 · Paolo Ambrosini, Fabrizio Loiacono, et al. · European Journal of Immunology · 25
PDF
PEOPLE (NTC03447678), a phase II trial to test pembrolizumab as first-line treatment in patients with advanced NSCLC with PD-L1 <50%: a multiomics analysis
2023 · Giuseppe Lo Russo, Arsela Prelaj, et al. · Journal for ImmunoTherapy of Cancer · 20
PDF
APOLLO 11 Project, Consortium in Advanced Lung Cancer Patients Treated With Innovative Therapies: Integration of Real-World Data and Translational Research
2023 · Arsela Prelaj, Monica Ganzinelli, et al. · Clinical Lung Cancer · 12
PDF
Real-World Outcomes of Molecular Tumor Board Treatment Recommendations
2025 · Federico Nichetti, Marta Brambilla, et al. · JCO Precision Oncology · 10
Immune-checkpoint targeting drug conjugates: a novel class of promising therapeutic agents for cancer treatment
2025 · Silvia Marchesi, Arianna Marinello, et al. · npj Precision Oncology · 9
PDF
Unleashing precision: A review of targeted approaches in pleural mesothelioma
2024 · Mario Occhipinti, Marta Brambilla, et al. · Critical Reviews in Oncology/Hematology · 9
Histologic Transformation of ALK-Rearranged Lung Adenocarcinomas to High-Grade LCNEC: Clinical and Molecular Description of Three Cases
2024 · Paolo Ambrosini, Daniela Miliziano, et al. · Clinical Lung Cancer · 8
PDF
Sex differences in patients with Non-Small Cell Lung Cancer harboring driver fusions treated with tyrosine kinase inhibitors: a systematic review
2024 · Rita Leporati, Édouard Auclin, et al. · Therapeutic Advances in Medical Oncology · 8
Systemic lupus erythematosus reactivation after chemoimmunotherapy in preexisting autoimmune disease
2022 · Andrea Spagnoletti, Marco Platania, et al. · Tumori Journal · 7
Molecular Characterization and Clinical Relevance of MGMT‐Silenced Pancreatic Cancer
2024 · Federico Nichetti, Marco Silvestri, et al. · Cancer Medicine · 5
PDF
Hot topics in genitourinary cancers: A multidisciplinary discussion on state-of-the-art and latest developments among international experts and patient advocacy
2024 · Alessandro Rametta, Paolo Ambrosini, et al. · Tumori Journal · 4
Refining High-Risk EGFR-Mutant Lung Cancer Patients: The Role of Adjusted Variant Allele Frequency in First-Line Osimertinib Therapy
2025 · Marta Brambilla, Francesca Barbetta, et al. · Clinical Lung Cancer · 3
Assessing suffering of patients on cancer treatment and of those no longer treated using ESAS–Total Care (TC)
2023 · Guido Miccinesi, Carla Ripamonti, et al. · Supportive Care in Cancer · 3
PDF
Exploring the Role of Immunotherapy-Based Treatments for Advanced Non–Small-Cell Lung Cancer With Novel Driver Alterations
2023 · Marta Brambilla, Teresa Beninato, et al. · Clinical Lung Cancer · 3
PDF
Clinician expertise and prompt engineering enhance cancer information extraction in electronic health records by small language models
2026 · Federica Corso, Vittoria Peppoloni, et al. · Communications Medicine · 2
PDF
APOLLO11: a bio-data-driven model for clinical and translational research in lung cancer
2026 · Arsela Prelaj, Leonardo Provenzano, et al. · npj Precision Oncology · 2
PDF
Benchmarking progression-free survival ratio as primary endpoint in precision oncology clinical trials
2025 · Federico Nichetti, Jennifer Hüllein, et al. · npj Precision Oncology · 2
PDF
Towards a new approach in pleural mesothelioma: Perioperative immunotherapy and its implications
2025 · Paolo Ambrosini, Alessia Stanzi, et al. · Critical Reviews in Oncology/Hematology · 2
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC
2026 · Arsela Prelaj, Vanja Miskovic, et al. · Nature Medicine · 1
Locoregional therapies in advanced and recurrent pleural mesothelioma: A systematic review
2025 · Paolo Ambrosini, Thierry Berghmans, et al. · Lung Cancer · 1
Acoustic biomarkers and AI: Transforming NSCLC detection and personalized care.
2025 · Chiara Giangregorio, Cristina Maria Licciardello, et al. · Journal of Clinical Oncology · 1
PDF
Real-World Eligibility for FLAURA, FLAURA2, and MARIPOSA in Patients with EGFR-Mutated Advanced NSCLC: A Retrospective Single-Center Study
2026 · Silvia Marchesi, Paolo Ambrosini, et al. · Cancers
Neurotoxicity associated with T-Cell engagers in solid tumors: A systematic review
2026 · Paolo Ambrosini, Catarina Lopes Fernandes, et al. · Therapeutic Advances in Medical Oncology
Works count: 45
Citation count: 352
H-index: 8
I10-index: 6
Year
Topic
Type